Abstract
SHARED DECISION MAKING IN THE CARE FOR THE GYNECOLOGIC CANCER PATIENT
Background and Aims:
Despite surgery and adjuvant chemotherapy, a large number of patients with ovarian cancer experience relapse. Treatment of recurrent disease is complex and strategies that involve both surgery and chemotherapy or surveillance can be discussed. This project aims to contribute to and evaluate clinical implementation of shared decision making (SDM) in ovarian cancer patients. A patient decision aid (PDA) will be developed to facilitate SDM related to treatment planning of the ovarian cancer patient with relapse
Methods:
The project includes development, testing, evaluation, and implementation of a PDA for women with relapsed ovarian cancer at three hospitals in Denmark. This wide test environment will enable national dissemination and ensure a uniform treatment of future Danish ovarian cancer patients. The test phase will include;1) Alpha test: Patients and clinicians are interviewed based on a structured interview guide based on internationally validated questionnaires used to assess, to what extent the PDA prepare the patient to make a decision.2) Beta test: Validated outcome measures, such as SDM-Q9, SDM-Q-DOC, OPTION and CollaboRATE will be used to asses patients and doctors experiences of SDM in consultations with patients experiencing a disease relapse at baseline before introduction of the PDA (Beta test 1) and after the use of the PDA (Beta test 2)
Results:
Based on an existing generic platform we have developed a PDA for relapsed platinum-sensitive as well as platinum-resistant ovarian cancer. The patient-clinician conversation in which the PDA is used consists of 5 steps:
Purpose of the PDA is presented
Patient is informed of the available treatment possibilities
Patients personal preferences is identified, what is important/concerns the patient
Patient's options and harms/benefits of each option are reviewed
A shared treatment decision is made with the patientConclusions:
The result of the project will be implemented broadly and systematically for the benefit of other cancer patients. The generic model can also be used to develop new tools for other clinical decisions within the health service
Background and Aims:
Despite surgery and adjuvant chemotherapy, a large number of patients with ovarian cancer experience relapse. Treatment of recurrent disease is complex and strategies that involve both surgery and chemotherapy or surveillance can be discussed. This project aims to contribute to and evaluate clinical implementation of shared decision making (SDM) in ovarian cancer patients. A patient decision aid (PDA) will be developed to facilitate SDM related to treatment planning of the ovarian cancer patient with relapse
Methods:
The project includes development, testing, evaluation, and implementation of a PDA for women with relapsed ovarian cancer at three hospitals in Denmark. This wide test environment will enable national dissemination and ensure a uniform treatment of future Danish ovarian cancer patients. The test phase will include;1) Alpha test: Patients and clinicians are interviewed based on a structured interview guide based on internationally validated questionnaires used to assess, to what extent the PDA prepare the patient to make a decision.2) Beta test: Validated outcome measures, such as SDM-Q9, SDM-Q-DOC, OPTION and CollaboRATE will be used to asses patients and doctors experiences of SDM in consultations with patients experiencing a disease relapse at baseline before introduction of the PDA (Beta test 1) and after the use of the PDA (Beta test 2)
Results:
Based on an existing generic platform we have developed a PDA for relapsed platinum-sensitive as well as platinum-resistant ovarian cancer. The patient-clinician conversation in which the PDA is used consists of 5 steps:
Purpose of the PDA is presented
Patient is informed of the available treatment possibilities
Patients personal preferences is identified, what is important/concerns the patient
Patient's options and harms/benefits of each option are reviewed
A shared treatment decision is made with the patientConclusions:
The result of the project will be implemented broadly and systematically for the benefit of other cancer patients. The generic model can also be used to develop new tools for other clinical decisions within the health service
Original language | English |
---|---|
Publication date | 15. Sept 2018 |
Publication status | Published - 15. Sept 2018 |
Event | 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) - Kyoto, Japan Duration: 14. Sept 2018 → 16. Sept 2018 https://igcs2018.com/ |
Conference
Conference | 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) |
---|---|
Country/Territory | Japan |
City | Kyoto |
Period | 14/09/2018 → 16/09/2018 |
Internet address |